Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.F Hoffmann-La Roche has decided to give back SGLT2 inhibitor CSG452's overseas development and marketing rights to Chugai Pharmaceutical.
Subscribe to our email newsletter
Chugai has licensed marketing and development rights for CSG452 to Roche in January 2007 as a treatment for type II diabetes.
Roche’s decision was backed by the priority review of its development pipeline which enforced the company to return back the rights of CSG452.
Chugai will seek for other partner regarding overseas development.
Chugai intends to submit regulatory filing for the compound in 2013.